The beneficial effects of dapagliflozin on the course of experimental urate nephrolithiasis
https://doi.org/10.20538/1682-0363-2017-1-73-79
Abstract
Aim of the study. Rate dapagliflozin effective in the prevention and treatment of experimental urate nephropathy.
Мaterials and methods. The study was conducted on 30 male rats Wistar stock weighing 220–310 g. For the formation of urate nephropathy in rats using reproduced earlier classic model inhibiting uricase, causing the development of hyperuricemia in rodents. The animal was determined daily urine content MC, total proteins, creatinine, and enzyme activity of renal dysfunction markers LDH, gamma-glutamyl and N-acetyl-β-D-glucosaminidase. After the experiment the rat blood obtained after decapitation determined content MC, creatinine, catalase, glutathione peroxidase, superoxide dismutase, reduced glutathione, thiobarbiturate-reactive products, total antioxidant activity and a common pro-oxidant activity. In the kidneys of rats was determined by the same parameters of free radical oxidation.
Results. It was found that prolonged use of dapagliflozin in the prophylactic and therapeutic regimes, despite a decline in urinary pH, significantly improves the condition of animals with experimental urate nephrolithiasis, as evidenced by a significant decrease in the level of uric acid in blood plasma and urine of rats, a decrease in LDH activity in urine and inhibition process is free -radical oxidation.
Сonclusion. Prolonged use of dapagliflozin in the prophylactic and therapeutic regimes, despite a decline urine pH, improved the urate nephrolithiasis, as evidenced by a significant decrease in the level of uric acid in blood plasma and urine of rats, decreased activity of LDH in urine and inhibition of the process of free-radical oxidation.
About the Authors
V. Yu. Perfil’ev
Altai State Medical University
Russian Federation
Russian Federation
Teacher of the Department of Pharmacology,
40, Lenin Av., Barnaul, 656038
Ya. F. Zverev
Altai State Medical University
Russian Federation
Russian Federation
DM, Professor, Department of Pharmacology,
40, Lenin Av., Barnaul, 656038
A. Yu. Zharikov
Altai State Medical University
Russian Federation
Russian Federation
DВSc, Professor, Department of Pharmacology,
40, Lenin Av., Barnaul, 656038
D. Yu. Luk’yanenko
Altai State Medical University
Russian Federation
Russian Federation
Student of 5th year, Medical-prophylactic Faculty,
40, Lenin Av., Barnaul, 656038
I. V. Lysenko
Altai State Medical University
Russian Federation
Russian Federation
Student of 6th year, Medical Faculty,
40, Lenin Av., Barnaul, 656038
O. Sh. Atabaeva
Altai State Medical University
Russian Federation
Russian Federation
PhD, Department of Pharmacology,
40, Lenin Av., Barnaul, 656038
References
1. Kalashnikova M.F. Metabolicheskiy sindrom: sovremennyy vzglyad na kontseptsiyu, metody profilaktiki i lecheniya [Metabolic syndrome: a modern view on the concept, methods of prevention and treatment.] // Effektivnaya farmakoterapiya – Effective pharmacotherapy. 2013; 52: 52–63 (in Russian).
2. Kim Y-J., Kim C-H., Sung E-J. et al. Association of nephrolithiasis with metabolic syndrome and its components // Metabolism. 2013; 62 (6): 808–813.
3. Antipova V.N., Kazeeva M.V. Kardiovaskulyarnyy risk i metabolicheskiy sindrom u bol’nykh podagroy [Cardiovascular risk and metabolic syndrome in patients with gout] // Izvestiya vysshikh uchebnykh zavedeniy. Povolzhskiy region. Meditsinskie nauki – Proceedings of the higher educational institutions. Volga region. Medical sciences. 2015; 1 (33): 112–122 (in Russian).
4. Bokarev I.N. Metabolicheskiy sindrom [Metabolic syndrome] // Klinicheskaya meditsina – Clinical medicine. 2014; 92 (8): 71–76 (in Russian).
5. Kalinchenko S.Yu., Tyuzikov I.A. Metabolicheskiy sindrom i urolitiaz (literaturnyy obzor) [Kalinchenko SY, Tyuzikov IA Metabolic syndrome and urolithiasis (literature review)] // Alfavit – Alphabet. 2011; 3 (16): 33–40 (in Russian).
6. Barskova V.G., Eliseev M.S., Denisov I.S. i dr. Chastota metabolicheskogo sindroma i soputstvuyushchikh zabolevaniy u bol’nykh podagroy. Dannye mnogotsentrovogo issledovaniya [Frequency of metabolic syndrome and related diseases in patients with gout. These multicenter study] // Nauchno-prakticheskaya revmatologiya – Scientific and practical rheumatology. 2012; 50 (6): 15–18 (in Russian).
7. Akman T., Binbay M., Erbin A. et al. The impact of metabolic syndrome on long-term outcomes of percutaneous nephrolithotomy (PCNL) // BJU Int. 2012; 110: E1079-E1083.
8. Bobulescu I.A., Maalouf N.M., Capolongo G. et al. Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes // Am. J. Physiol. Renal Physiol. 2013; 305: E1498-E1503.
9. Daskalopoulou S.S., Mikhailidis D.P., Elisaf M. Prevention and treatment of the metabolic syndrome // Angiology. 2004; 55 (6): 3145–3152.
10. Sakhaee K., Maalouf N.M. Metabolic syndrome and uric acid nephrolithiasis. Semin // Nephrol. 2008; 28 (2): 174–180.
11. Abate N., Chandalia M., Cabo-Chan A.V. Jr. et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance // Kidney Int. 2004; 65: 386–392.
12. Cameron M.A., Maalouf N.M., Adams-Huet B. et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis // J. Am. Soc. Nephrol. 2006; 17: 1422–1428.
13. Mkrtumyan A.M. Forsiga – unikal’nyy podkhod k lecheniyu bol’nykh sakharnym diabetom tipa 2 na vsekh etapakh progressirovaniya zabolevaniya [Forsiga - a unique approach to the treatment of patients with type 2 diabetes at all stages of disease progression] // Effektivnaya farmakoterapiya – Effective pharmacotherapy. 2016; 4: 22–31 (in Russian).
14. Macdonald F.R., Peel J.E., Jones H.B. et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats // Diabetes Obes. Metab. 2010; 12: 1004–1012.
15. Zhang L., Feng Y., List J., Kasichayanula S., Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes // Metab. 2010; 12: 510–516.
16. Perfil’ev V.Yu., Zverev Ya.F., Bryukhanov V.M., Cherdantseva T.M., Bobrov I.P. Uspeshnyy opyt modelirovaniya uratnoy nefropatii u krys [The successful experience of modeling urate nephropathy in rats] // Nefrologiya – Nephrology. 2016; 4 (20): 93–97 (in Russian).
17. Zverev Ya.F., Bryukhanov V.M. Sovremennyy vzglyad na mekhanizmy razvitiya uratnogo nefrolitiaza [The modern view of the mechanisms of urate nephrolithiasis] // Klinicheskaya nefrologiya – Clinical Nephrology. 2015; 5–6: 39–47 (in Russian).
18. Vander A. Fiziologiya pochek. Pod red. Yu.V. Natochina / Per s angl. G.A. Lapisa. [Renal physiology. Ed. Yu.V. Natochin / Translated from English G.A. Lapis. St.-Petersburg: Piter, 2000: 256. (in Russian).
19. Rosenstock J., Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with sglt2 inhibitors // Diabetes Care. 2015; Sep; 38 (9): 1638–1642.
20. Ogawa W., Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors // J. Diabetes Investig. 2016; 7(2): 135–138.
21. Nissim I., States B., Nissim I. et al. Hormonal regulation of glutamine metabolism by OK cells // Kidney Int. 1995; 47: 96–105.
22. Titov V.N., Dmitriev V.A., Gushchina O.V. Oshchepkova E.V., Yashin A.Ya. Fiziko-khimicheskaya aktivnost’ mochevoy kisloty. Giperurikemiya – narushenie biologicheskikh funktsiy endoekologii i adaptatsii, biologicheskikh reaktsiy ekskretsii, vospaleniya i gidrodinamicheskogo arterial’nogo davleniya [Physico-chemical activity of uric acid. Hyperuricemia - violation of biological functions Endoecology and adaptation of biological reactions excretion, inflammation and blood pressure hydrodynamic] // Uspekhi sovr. biol. – Successes of modern biology. 2011; 131 (5): 483–502 (in Russian).
23. Glantzounis G.K., Tsimoyiannis E.C., Kappas A.M., Galaris D.A. Uric acid and oxidative stress // Curr. Pharm. Des. 2005; 32 (11): 4145–4151.
Review
For citations:
Perfil’ev V.Yu., Zverev Ya.F., Zharikov A.Yu., Luk’yanenko D.Yu., Lysenko I.V., Atabaeva O.Sh. The beneficial effects of dapagliflozin on the course of experimental urate nephrolithiasis. Bulletin of Siberian Medicine. 2017;16(1):73-79. (In Russ.) https://doi.org/10.20538/1682-0363-2017-1-73-79
Views:
1791
Email this article 